{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:32:00Z","timestamp":1784097120255,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,12]]},"DOI":"10.7759\/cureus.17126","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T14:15:08Z","timestamp":1628777708000},"source":"Crossref","is-referenced-by-count":3,"title":["Role of Vasodilator Therapy in Acute Heart Failure"],"prefix":"10.7759","author":[{"given":"Aisha","family":"Batool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Malkawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Siraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin EJ","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, et al.. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019, 139:e56-e528. 10.1161\/CIR.0000000000000659","journal-title":"Circulation"},{"key":"ref2","unstructured":"Underlying Cause of Death 1999-2019. (2019). Accessed. January 7, 2019: https:\/\/wonder.cdc.gov\/wonder\/help\/ucd.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2003.025270","article-title":"Clinical epidemiology of heart failure","volume":"93","author":"Mosterd A","year":"2007","unstructured":"Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007, 93:1137-46. 10.1136\/hrt.2003.025270","journal-title":"Heart"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016, 37:2129-200. 10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.09.022","article-title":"Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database","volume":"47","author":"Yancy CW","year":"2006","unstructured":"Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006, 47:76-84. 10.1016\/j.jacc.2005.09.022","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2016.04.014","article-title":"Timing and causes of readmission after acute heart failure hospitalization-insights from the Heart Failure Network Trials","volume":"22","author":"Vader JM","year":"2016","unstructured":"Vader JM, LaRue SJ, Stevens SR, et al.. Timing and causes of readmission after acute heart failure hospitalization-insights from the Heart Failure Network Trials. J Card Fail. 2016, 22:875-83. 10.1016\/j.cardfail.2016.04.014","journal-title":"J Card Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.872","article-title":"Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"19","author":"Harjola VP","year":"2017","unstructured":"Harjola VP, Mullens W, Banaszewski M, et al.. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017, 19:821-36. 10.1002\/ejhf.872","journal-title":"Eur J Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703100","article-title":"Diuretic treatment in heart failure","volume":"377","author":"Ellison DH","year":"2017","unstructured":"Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017, 377:1964-75. 10.1056\/NEJMra1703100","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-307461","article-title":"The pathophysiology of hypertensive acute heart failure","volume":"101","author":"Viau DM","year":"2015","unstructured":"Viau DM, Sala-Mercado JA, Spranger MD, O'Leary DS, Levy PD. The pathophysiology of hypertensive acute heart failure. Heart. 2015, 101:1861-7. 10.1136\/heartjnl-2015-307461","journal-title":"Heart"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.08.001","article-title":"2019 ACC Expert Consensus Decision Pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"74","author":"Hollenberg SM","year":"2019","unstructured":"Hollenberg SM, Warner Stevenson L, Ahmad T, et al.. 2019 ACC Expert Consensus Decision Pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019, 74:1966-2011. 10.1016\/j.jacc.2019.08.001","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor CM","year":"2011","unstructured":"O'Connor CM, Starling RC, Hernandez AF, et al.. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011, 365:32-43. 10.1056\/NEJMoa1100171","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601895","article-title":"Effect of ularitide on cardiovascular mortality in acute heart failure","volume":"376","author":"Packer M","year":"2017","unstructured":"Packer M, O'Connor C, McMurray JJV, et al.. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017, 376:1956-64. 10.1056\/NEJMoa1601895","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801291","article-title":"Effects of Serelaxin in patients with acute heart failure","volume":"381","author":"Metra M","year":"2019","unstructured":"Metra M, Teerlink JR, Cotter G, et al.. Effects of Serelaxin in patients with acute heart failure. N Engl J Med. 2019, 381:716-2. 10.1056\/NEJMoa1801291","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.18598","article-title":"Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial","volume":"322","author":"Kozhuharov N","year":"2019","unstructured":"Kozhuharov N, Goudev A, Flores D, et al.. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial. JAMA. 2019, 322:2292-302. 10.1001\/jama.2019.18598","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200007273430403","article-title":"Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group","volume":"343","author":"Colucci WS","year":"2000","unstructured":"Colucci WS, Elkayam U, Horton DP, et al.. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000, 343:246-53. 10.1056\/NEJM200007273430403","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.12.1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial","volume":"287","author":"Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF)","year":"2002","unstructured":"Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002, 287:1531-40. 10.1001\/jama.287.12.1531","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000159340.93220.E4","article-title":"Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure","volume":"111","author":"Sackner-Bernstein JD","year":"2005","unstructured":"Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005, 111:1487-91. 10.1161\/01.CIR.0000159340.93220.E4","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.15.1900","article-title":"Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials","volume":"293","author":"Sackner-Bernstein JD","year":"2005","unstructured":"Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. 2005, 293:1900-1905. 10.1001\/jama.293.15.1900"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink JR","year":"2013","unstructured":"Teerlink JR, Cotter G, Davison BA, et al.. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013, 381:29-39. 10.1016\/S0140-6736(12)61855-8","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2013.09.015","article-title":"Pathophysiology and etiology of heart failure","volume":"32","author":"Johnson FL","year":"2014","unstructured":"Johnson FL. Pathophysiology and etiology of heart failure. Cardiol Clin. 2014, 32:9-19, vii. 10.1016\/j.ccl.2013.09.015","journal-title":"Cardiol Clin"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00638","article-title":"Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology","volume":"10","author":"Gevaert AB","year":"2019","unstructured":"Gevaert AB, Boen JRA, Segers VF, Van Craenenbroeck EM. Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology. Front Physiol. 2019, 10:638. 10.3389\/fphys.2019.00638","journal-title":"Front Physiol"},{"key":"ref22","article-title":"Heart failure with mid-range ejection fraction - a new category of heart failure or still a gray zone","volume":"11","author":"Andronic AA","year":"2016","unstructured":"Andronic AA, Mihaila S, Cinteza M. Heart failure with mid-range ejection fraction - a new category of heart failure or still a gray zone. Maedica (Bucur). 2016, 11:320-4.","journal-title":"Maedica (Bucur)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)08417-1","article-title":"Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema","volume":"7","author":"Cotter G","year":"1998","unstructured":"Cotter G, Metzkor E, Kaluski E, et al.. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998, 7:389-93. 10.1016\/S0140-6736(97)08417-1","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2007.02.022","article-title":"Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis","volume":"50","author":"Levy P","year":"2007","unstructured":"Levy P, Compton S, Welch R, et al.. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med. 2007, 50:144-52. 10.1016\/j.annemergmed.2007.02.022","journal-title":"Ann Emerg Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/58754-role-of-vasodilator-therapy-in-acute-heart-failure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:28:39Z","timestamp":1707506919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/58754-role-of-vasodilator-therapy-in-acute-heart-failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.17126","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,12]]}}}